

## Original Article

# The association between blood concentration of 25-hydroxyvitamin D and sarcopenia: a meta-analysis

Jing Luo MS<sup>1</sup>, Zhenyu Quan PhD<sup>2</sup>, Song Lin PhD<sup>1</sup>, Lianhua Cui PhD<sup>1</sup>

<sup>1</sup>Department of Public Health, Medical College of Qingdao University, Qingdao, Shandong Province, China

<sup>2</sup>Medical School of Yanbian University, Yanji City, Yanbian Korean Autonomous Prefecture, Jilin, China

**Background and Objectives:** Associations between blood 25-hydroxyvitamin D (25(OH)D) concentration and sarcopenia remain controversial; thus, this meta-analysis was conducted to explore the relationship between blood 25(OH)D concentration and sarcopenia. **Design:** We searched the PubMed and EMBASE databases for relevant published observational studies that investigated blood 25(OH)D concentration and sarcopenia up to June 2017. We then investigated data from these studies that compared blood 25(OH)D concentrations between the sarcopenia and healthy control groups. A random-effect model was used to calculate the pooled weighted mean difference (WMD) of blood 25(OH)D concentration with a 95% confidence interval (95% CI). **Results:** Twelve studies (eight cross-sectional, two matched case-control, and two prospective cohort studies) with a total of 22,590 individuals were included. Sarcopenic individuals had lower blood 25(OH)D concentrations than healthy controls (WMD=-2.14, 95% CI: -2.81--1.48;  $I^2=74.6\%$ ). Subgroup analysis showed that the methods of assessing both blood 25(OH)D concentrations and sarcopenia might be sources of heterogeneity, and further showed that studies excluding obese individuals and different sarcopenia assessment criteria enhanced the relationship. Sensitivity analysis by one-study-removed confirmed the robustness of these results. **Conclusions:** Our study shows that sarcopenic adults have lower blood 25(OH)D concentrations. Further high-quality large-scale prospective cohort studies are needed to confirm these findings.

**Key Words:** sarcopenia, vitamin D, 25-hydroxyvitamin D, muscle mass, meta-analysis

## INTRODUCTION

Sarcopenia, which is characterized by a reduction in muscle mass and strength, as well as a decline in physical performance with age, has become an important worldwide public health problem. Sarcopenia has long been regarded as a characteristic of natural aging rather than a disease; however, recent studies have shown that sarcopenia is associated with various diseases such as cancer, heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, and neurodegenerative disorders.<sup>1</sup> Additionally, sarcopenia is also accompanied by worse health outcomes, including increased mortality rates, longer hospitalization times, and greater need for rehabilitation care after hospital discharge.<sup>2</sup> As a major clinical problem associated with age, there is a progressive reduction in the size and number of muscle fibers, which can result in a decrease in muscle mass of approximately 40% between the ages of 25 and 80.<sup>3,4</sup> Many studies have shown that vitamin D deficiency contributes to sarcopenia development and that vitamin D supplements can increase muscle quality (e.g., gait speed, handgrip strength).<sup>5,6</sup>

Vitamin D is a fat-soluble vitamin that regulates calcium and phosphorous homeostasis, as well as bone mineralization.<sup>7</sup> Its active form is 1,25 dihydroxy vitamin D<sub>3</sub> (1,25(OH)<sub>2</sub>D)<sup>8</sup> and the major circulating metabolite is 25-hydroxyvitamin D(25(OH)D).<sup>9</sup> Although the latter is not the most active metabolite, blood concentrations of total 25(OH)D are routinely used to assess blood vitamin D

status in clinical practice.<sup>10</sup> There has been an increasing appreciation of the role of vitamin D in maintaining muscle health and physical activity,<sup>11,12</sup> as its insufficiency can cause muscle weakness and a decline in bone mineral density, as well as an increase in the risk of recurrent falls in elderly adults.<sup>13</sup> The association between low blood 25(OH)D concentration and increased risk of falls has been reported in many studies.<sup>14,15</sup> Falls are the primary clinical sign of reduced muscle function, which is the long-term outcome of losing muscle mass.

Several recent studies have focused on sarcopenia and its related risk factors. Yoshimura et al<sup>16</sup> performed a systematic review and meta-analysis based on randomized controlled trials to explore the effectiveness of exercise, nutrition, drugs, and combinational interventions for treating sarcopenia in older people. Another systematic review and meta-analysis<sup>17</sup> based on randomized controlled trials assessed the effects of vitamin D supplementation on muscle strength and muscle mass. However, no

**Corresponding Author:** Dr Lianhua Cui, Department of Public Health, Medical College of Qingdao University, Dengzhou Road 38, Qingdao, Shandong Province, China.

Tel: 053282991503; Fax: 86053283812434.

Email: qdlhcui@163.com

Manuscript received 09 May 2018. Initial review completed 07 June 2018. Revision accepted 20 August 2018.

doi: 10.6133/apjcn.201811\_27(6).0013

comprehensive meta-analysis has addressed the role of blood 25(OH)D concentration on sarcopenia. Some studies have shown a relationship between blood 25(OH)D concentration and sarcopenic adults;<sup>5,18-21</sup> however, these results are not unequivocal. Thus, we conducted this meta-analysis to investigate the underlying association between blood 25(OH)D concentration and sarcopenia.

## PARTICIPANTS AND METHODS

This meta-analysis was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement.<sup>22</sup>

### Search strategy

Two authors (J.L. and S.L.) independently searched the PubMed and EMBASE databases for relevant observational published studies that investigated serum, plasma and blood 25(OH)D concentration and sarcopenia up to June 2017 (Supplemental figure 1). A manual search using references from the retrieved studies was also performed.

### Eligibility criteria and quality assessment

Our inclusion criteria were as follows: (i) observational original articles evaluating the blood concentration of 25(OH)D in both sarcopenia patients and the general population; (ii) sarcopenia was diagnosed based on the adjusted appendicular muscle skeletal muscle mass measured by dual-energy x-ray absorptiometry (DEXA)<sup>23</sup> or bioelectrical impedance (BIA);<sup>24</sup> and (iii) sarcopenia was considered the case and non-sarcopenia was considered the control.

Our exclusion criteria were as follows: (i) participants were clinical patients from hospital or care settings; and (ii) studies not published as full reports, letters, or case-only studies.

The quality of all studies was also independently assessed by the two authors listed above using the Newcastle-Ottawa scale for cohort, case-control studies in three aspects, including the selection of study participants, the comparability of the groups, and assessment of outcome measures. Cross-sectional studies were evaluated by the modified Newcastle-Ottawa Scale.<sup>25</sup> Any differences were resolved by consensus. Studies with a Newcastle-Ottawa scale score  $\geq 5$  were regarded as high quality.

### Data extraction

The following study characteristics were extracted from each study using a standardized record form: surname of the first author, year of publication, study location, characteristics of the study population (e.g., cohort size and demographics) assessment criteria of sarcopenia, and blood 25(OH)D concentration. Data extraction was independently extracted by the two authors (J.L. and S.L.). Any disagreement was resolved by referring back to the original studies.

### Statistical analysis

All analyses were conducted using Stata11.0 software (StataCorp, College Station, TX, USA). Unless otherwise specified, a  $p$ -value  $< 0.05$  was considered significant. The pooled weighted mean difference (WMD) and its 95%

confidence interval (CI) were used for this meta-analysis of blood 25(OH)D concentration and sarcopenia. We pooled the estimates across studies using the random-effect model (DerSimonian-Laird). Study heterogeneity was measured using the Cochran's  $Q$  and  $I^2$  statistics, assuming that  $p \leq 0.10$  for the former and  $p \geq 50\%$  for the latter indicated significant and substantial heterogeneity.<sup>26</sup> We conducted subgroup analyses to investigate the potential differences and heterogeneity according to methods used to detect blood 25(OH)D concentrations, methods of measuring skeletal muscle mass, whether studies excluded obese individuals, and the assessment criteria of sarcopenia (muscle mass alone or combined with muscle quality) were conducted. Sensitivity analysis was conducted to evaluate the robustness of results. When the blood 25(OH)D concentration were reported in nmol/L, we divided both the mean and SD by 2.5 to convert to ng/ml.<sup>27</sup> Small-study effects were evaluated using a funnel plot and Egger's test.<sup>28</sup>

## RESULTS

### Literature search

We initially identified 761 potential articles, including 594 from EMBASE and 167 from PubMed. After excluding duplicate articles and reviewing titles and abstracts, 559 were removed. Then, 50 articles underwent full-text review according to the inclusion criteria, which excluded 38. In total, 12 articles were included in our final meta-analysis for estimating the association between blood 25(OH)D concentration and sarcopenia. The selection process is shown in Figure 1.

### Study characteristics

All investigated subjects, which included 6,357 sarcopenic individuals and 16,233 healthy controls, were from the community. The mean age of sarcopenic individuals ranged from 50<sup>29</sup>–88<sup>30</sup> years, and that of healthy controls ranged from 50<sup>29</sup>–86<sup>30</sup> years; 54.65% of all individuals were women. As for study design, eight studies were cross-sectional studies,<sup>5,18,29-34</sup> two were matched case-control studies<sup>19,20</sup> and two were prospective cohort studies.<sup>21,35</sup> With regard to study location, eight studies were conducted in Korea,<sup>5,18,21,29,31,32,34,35</sup> and one study was conducted in each of following countries: Australia,<sup>30</sup> United Kingdom,<sup>19</sup> Netherlands,<sup>33</sup> and Brazil.<sup>20</sup> All studies provided blood 25(OH)D concentrations; six studies<sup>5,18,21,31,32,35</sup> used a radioimmunoassay kit (RIA)<sup>36</sup> to detect 25(OH)D, three<sup>19,31,33</sup> used the chemiluminescence micro-particulate immunoassay (CIA)<sup>37</sup> method, one<sup>21</sup> used HPLC<sup>38</sup> and two<sup>29,34</sup> did not report their methods. Sarcopenia was diagnosed by dual energy x-ray absorptiometry (DEXA)<sup>39</sup> in 10 articles<sup>5,18,20,21,29-32,34,35</sup> and by bioelectric impedance analysis (BIA)<sup>40</sup> in two articles.<sup>19,33</sup> The data from eight articles<sup>5,19,20,30-34</sup> were reported as mean $\pm$ SD, three studies<sup>18,21,35</sup> gave mean $\pm$ inter quartile range, and one (Park S et al) provided mean $\pm$ 95% CI. All data were converted to weighted mean difference (WMD) $\pm$ SD. The characteristics of the included articles are summarized in Table 1. The Newcastle–Ottawa scores of each study were not less than 5, indicating that the methodological quality was generally good. The quality assessments of the included studies are shown in Supplemental table 1.

**Table 1.** Basic characteristics of studies.

Vitamin D assessment	Sarcopenia assessment	Gender (Female %)	Sample size, n	Baseline age, years	Study design	Country	Authors (Year)
CIA	BIA	M/F (59.1%)	sarcopenia 66 control 66	sarcopenia 71.1±4.4 control 71.0±4.4	matched case-control	United Kingdom	Verlaan et al (2017)
RIA	DEXA	M/F (56.67%)	sarcopenia 746 control 217	sarcopenia 71.54±0.31 control 69.61±0.22	cross-sectional	Korea	Oh et al (2017)
RIA	DEXA	M	sarcopenia 91 control 720	sarcopenia 74.5±5.6 control 71.5±5.0	cross-sectional	Korean	Kim et al (2017)
RIA	DEXA	M/F (50.31%)	sarcopenia 835 control 3096	sarcopenia 57.9±14.6 control 51.3±14.6	cross-sectional	Korean	Hwang et al (2017)
CIA	BIA	M/F 51.54%	sarcopenia 53 control 174	≥65	cross-sectional	Netherlands	Ter et al (2016)
CIA	BIA	M/F (59.1%)	sarcopenia 66 control 66	sarcopenia 71.1±4.4 control 71.0±4.4	matched case-control	United Kingdom	Verlaan et al (2017)
RIA	DEXA	M/F (56.67%)	sarcopenia 746 control 217	sarcopenia 71.54±0.31 control 69.61±0.22	cross-sectional	Korea	Oh et al (2017)
RIA	DEXA	M	sarcopenia 91 control 720	sarcopenia 74.5±5.6 control 71.5±5.0	cross-sectional	Korean	Kim et al (2017)
RIA	DEXA	M/F (50.31%)	sarcopenia 835 control 3096	sarcopenia 57.9±14.6 control 51.3±14.6	cross-sectional	Korean	Hwang et al (2017)
CIA	BIA	M/F 51.54%	sarcopenia 53 control 174	≥65	cross-sectional	Netherlands	Ter et al (2016)
CIA	DEXA	65%	sarcopenia:284 control 1	sarcopenia: 81±7 control: 79±7	cross-sectional	Australia	Huo et al (2016)
HPLC	DEXA	100%	sarcopenia 35 control 70	sarcopenia 70.6 ±5.7 control: 70.6±4.9	matched case-control	Brazil	de Souza Genaro et al (2015)
RIA	DEXA	63.05%	sarcopenia 128 control 324	sarcopenia 60±11.11 control: 51±17.04	baseline data of cohort study	Korea	Hong et al (2014)
N/A	DEXA	58.25%	sarcopenia 4611 control 2597	≥50	cross sectional analysis	Korea	Park S et al (2014)
N/A	DEXA	57.53%	Sarcopenia 1248 control 1695	male: sarcopenia 69.7±6.6; control 68.5±6.0 female: sarcopenia 69.4±6.2; non-sarcopenia 69.3±6.6	cross-sectional	Korea	Chung JY et al (2013)
RIA	DEXA	63.49%	Sarcopenia 28 non-sarcopenia 186	Male/Female: sarcopenia: 53.0/50.9±10.7 non-sarcopenia: 49.9±16.9/43.1±14.3	baseline data of cohort study	Korea	Kim TN et al (2013)
RIA	DEXA	56.45%	sarcopenia 246 non-sarcopenia 2923	sarcopenia 68.0±8.9 non-sarcopenia 63.6±9.2	cross-sectional study	Korea	Kim MK et al (2011)

DEXA: Dual energy x-ray absorptiometry; BIA: bioelectric impedance analysis; RIA: radioimmunoassay kit; CIA: chemiluminescence micro-particulate immunoassay; HPLC: high performance liquid chromatography; N/A: not available.

**Association between blood 25(OH)D concentration and sarcopenia**

Figure 2 shows the results of the meta-analysis of the 12 studies regarding blood 25(OH)D concentration and sar-

copenia. These results revealed that sarcopenic patients had lower blood 25(OH)D concentrations compared with the healthy controls (WMD=-2.14, 95% CI: -2.81- -1.48). The statistical heterogeneity was high with an  $I^2$




Figure 1. Flow diagram of literature search.




Figure 2. Forest plot of all included studies.

of 74.6%.

Considering that high heterogeneity was found, sub-analyses were conducted to explore the possible sources of heterogeneity. Subgroup analyses of the methods used to detect blood 25(OH)D concentrations, methods of measuring skeletal muscle mass, whether studies excluded obese individuals, and the assessment criteria of sarcopenia were conducted. We first conducted a sub-analysis between different measurement methods for blood 25(OH)D (Supplemental figure 2). Sub-analyses showed a negative association between blood 25(OH)D concentrations and sarcopenia in RIA studies (WMD=-1.59, 95% CI, -2.30-0.89; k=6), CIA studies (WMD=-3.83, 95% CI, -6.38-1.29; k=3), and N/A studies (WMD=-2.57, 95%CI, -3.03-2.12; k=2); however this effect was not seen in the HPLC study,<sup>25</sup> which might be explained by the small number of included studies and their sample sizes. Both RIA and CIA studies continued to demonstrate moderate heterogeneity, with  $I^2$  of 65.6% and 53.9%, respectively. While the N/A subgroup showed low heterogeneity, with an  $I^2$  of 0. Then we conducted a sub-analysis between the different measurement methods for skeletal muscle mass (Supplemental figure 3). DEXA studies (WMD=-2.08, 95% CI, -2.76-1.41;  $I^2=77.2%$ , k=10) showed a negative association between blood 25(OH)D concentration and sarcopenia. This effect was not seen in BIA studies (WMD=-3.21, 95% CI, -7.55-1.14;  $I^2=67.5%$ , k=2). The next sub-analysis aimed to distinguish between studies that excluded obese individuals or not (Supplemental figure 4). Both studies that excluded (WMD=-1.89, 95% CI, -3.19-0.59; k=4) and those that did not exclude obese individuals (WMD=-2.27, 95% CI, -2.98-1.57; k=8) showed a significant association between blood 25(OH)D concentrations and sarcopenia. They all also continued to demonstrate moderate heterogeneity with  $I^2$  of 74.0% and 63.0%, respectively. The last sub-analysis was conducted

to distinguish the sarcopenia assessment criteria, which included muscle quality (e.g., gait speed, handgrip strength) or not (Supplemental figure 5). Both assessment criteria demonstrated moderate heterogeneity, with  $I^2$  of 53.9% and 75.2%, respectively. Studies in which sarcopenia was evaluated by combined muscle mass and muscle quality showed lower blood 25(OH)D concentrations (WMD=-3.83, 95% CI, -6.38-1.29, k=3) than studies that only focused on muscle mass (WMD=-1.90, 95% CI, -2.54-1.25, k=9); however, they all showed a negative association between blood 25(OH)D concentrations and sarcopenia.

#### Sensitivity analysis

Finally, a sensitivity analysis was performed to evaluate the robustness of these results. We conducted a one-study-removed sensitivity analysis (Supplemental figure 6) and we excluded studies that were only conducted on men or women. These statistical results still showed a significant difference (WMD=-2.37, 95% CI, -3.21-1.62; k=10). Thus, these sensitivity analyses suggested that the results were stable and reliable.

#### Small-study effect evaluation

To investigate potential small study effects, funnel plots and quantitative assessments via Egger's test were performed (Figure 3). The results of the funnel plot and an Egger's test ( $p=0.301$ ) did not suggest any obvious small study effects.

#### DISCUSSION

The purpose of this study was to evaluate if blood 25(OH)D concentration was associated with sarcopenia. Pooled results from 12 studies showed that individuals with sarcopenia had lower blood 25(OH)D concentrations compared with the non-sarcopenia population. Interestingly, we found that this effect was not seen in sub-




Figure 3. Small-study effect evaluation.

analyses of studies that used HPLC to measure blood 25(OH)D and those that used BIA methods to assess skeletal muscle mass. Compared with the RIA and CIA methods for measuring blood 25(OH)D, the pooled effects of HPLC studies might be explained by the small number of included studies and sample sizes (35 with sarcopenia and 70 non-sarcopenia). A previous study<sup>41</sup> showed that DEXA estimates of percentage body fat were higher and that lean mass was lower than the values obtained using BIA, meanwhile sarcopenia is characterized by a higher fat accumulation in the muscle, which might be a reason for inconsistencies of sub-analyses that used body composition. It is worth mentioning that the assessment criteria of sarcopenia were extremely varied among the included studies, which might confound the association between blood 25(OH)D concentration and sarcopenia. A lower pooled blood 25(OH)D concentration was found in our included studies that evaluated sarcopenia based on muscle mass and strength compared with those that used muscle mass alone. Evaluating sarcopenia by combining muscle mass and strength, which considers both structure and function, was better for predicting disability than muscle mass alone. Additionally, another meta-analysis<sup>17</sup> that included 30 randomized controlled trials shows that vitamin D supplementation had a small but significant positive effect on muscle strength, but had no significant effect on muscle mass. Another study<sup>42</sup> demonstrated that the loss of muscle mass was a major determinant of muscle strength loss during aging; therefore, blood 25(OH)D concentrations may play an important role that bridges loss of muscle mass and decline of muscle strength. Reduced muscle mass may lead to a decline in blood 25(OH)D concentration, which contributes to the development of reduced muscle strength, and this decline in strength is much more rapid than the concomitant loss of muscle mass, demonstrating reduced muscle quality.<sup>42</sup> This result implies that there is a certain link between sarcopenia and vitamin D. The potential physiological mechanisms of the association between blood 25(OH)D and sarcopenia still require more exploration.

#### **Potential biological mechanisms**

Several potential biological links might exist between blood 25(OH)D and sarcopenia. First, muscle fibers are associated with blood 25(OH)D concentration. Histological sections of 25(OH)D-deficient individuals show muscle fiber atrophy, enlarged inter fibrillar spaces, fat infiltration, fibrosis and glycogen granules,<sup>43</sup> all of which can lead to a decline in muscle function. Moreover, individuals with low vitamin D demonstrate a preferential atrophy of type 2 muscle fibers, combined with reduced muscle strength and proximal muscle weakness.<sup>43</sup> These changes include denervation of motor units and a net conversion of fast type 2 muscle fibers into slow type 1 fibers with the resulting loss in muscle quality necessary for daily activities.<sup>44</sup> Second, both the decline in blood 25(OH)D and muscle mass loss are age-related changes.<sup>45,46</sup> The latter is closely related to the decline in the expression of vitamin D receptors (VDRs),<sup>47</sup> which may limit the biologically active form of vitamin D. This suggests that vitamin D exerts its principal actions by

binding to VDRs on muscle tissues.<sup>43,48</sup> Furthermore, decreased vitamin D levels in older persons may lead to a decline in VDR expression because of decreased stimulation, and thus down regulation of receptor expression.<sup>49-51</sup> Over time, this may impair protein synthesis in muscle cells,<sup>53,54</sup> which also results in a decrease in type 2 fibers and reduces muscle strength,<sup>49,55</sup> eventually leading to sarcopenia. The presence of VDR in skeletal muscle myocytes could demonstrate the relationship between blood 25(OH)D concentration and muscle synthesis and/or altered contractility.<sup>56</sup> In addition to the aging process, a number of studies have shown that physical activity is associated with both sarcopenia and low blood 25(OH)D concentrations.<sup>57</sup> Some studies have shown that physical inactivity contributes to sarcopenia development.<sup>58</sup> In middle-aged and older adults, low skeletal muscle mass may contribute to the development of low blood 25(OH)D levels due to reduced physical activity, which promotes a sedentary lifestyle that is linked with reduced sunlight exposure,<sup>59</sup> which is the most important source of vitamin D. Considering most adjusted variables included factors such as age, gender, smoking and alcohol consumption, the association between sarcopenia and blood 25(OH)D concentration could not be explained simply by aging and physical inactivity, suggesting that other specific mechanisms may exist. As mentioned previously, chronic inflammation has been recognized as another key component of sarcopenia,<sup>60,61</sup> while vitamin D also has an active role in reducing inflammation.<sup>62</sup> In summary, exercise and nutritional interventions may be a good choice for treating sarcopenic adults with vitamin D deficiency; however, the details will need to be researched in future high-quality randomized controlled trials.

#### **Directions for further research**

Blood 25(OH)D concentrations vary by sex; yet how gender influences the prevalence and effects of blood 25(OH)D concentration on sarcopenia remains an open question. Additionally, the impact of blood 25(OH)D concentration on sarcopenia in middle-aged and older obese adults is unknown. Despite the study population including obese individuals, aging muscles can be infiltrated by fat, and most methods for measuring skeletal muscle mass use DEXA, which does not distinguish between fat and lean muscle, so it is unclear what is being measured to ensure it is "lean muscle mass." As critical confounders, the degree to which skeletal muscle adipose tissue infiltration (myosteatosis) and vitamin D deficiency impact sarcopenia still require further study.

#### **Strengths and limitations**

Our study had multiple strengths. First, our analysis focus on the association between blood 25(OH)D concentration and sarcopenia primarily in middle-aged and older adults. It was also a representative sample in which a decrease in total lean body mass began to appear. Additionally, the pooled effect estimates did not change significantly whether adjusted for potential confounders or not, indicating that our results were reliable. Nevertheless, this meta-analysis also had several limitations. First, we were limited to performing this meta-analysis on observational studies. This meta-analysis mainly came from cross-

sectional studies, thus, a directional causality between blood 25(OH)D concentrations and sarcopenia in middle-aged and older adults cannot be ascertained and will require future cohort studies for confirmation. Second, several factors, such as sex, obesity, methods for measuring blood 25(OH)D and sarcopenia, could lead to heterogeneity. Third, the subjects of this meta-analysis were mostly Asian (and most of them Korean), which may lead to potential publication bias; better-designed studies with populations from other countries are needed.

In summary, our meta-analysis demonstrated a significant negative association between blood 25(OH)D concentration and sarcopenia. However, related studies are still deficient. Further well-designed cohort and randomized controlled trials studies are required to confirm the relationship between blood 25(OH)D and sarcopenia.

#### AUTHOR DISCLOSURES

The authors declare no conflicts of interest.

#### REFERENCES

1. Chang KV, Hsu TH, Wu WT, Huang KC, Han DS. Is sarcopenia associated with depression? A systematic review and meta-analysis of observational studies. *Age Ageing*. 2017; 46:738-46. doi: 10.1093/ageing/afx094.
2. Peterson SJ, Braunschweig CA. Prevalence of sarcopenia and associated outcomes in the clinical setting. *Nutr Clin Pract*. 2016;31:40-8. doi: 10.1177/0884533615622537.
3. Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. *J Am Med Dir Assoc*. 2011;12:249-56. doi: 10.1016/j.jamda.2011.01.003.
4. Sayer AA, Robinson SM, Patel HP, Shavlakadze T, Cooper C, Grounds MD. New horizons in the pathogenesis, diagnosis and management of sarcopenia. *Age Ageing*. 2013;42: 145-50. doi: 10.1093/ageing/afs191.
5. Kim MK, Baek KH, Song KH, Il Kang M, Park CY, Lee WY, Oh KW. Vitamin D deficiency is associated with sarcopenia in older Koreans, regardless of obesity: the Fourth Korea National Health and Nutrition Examination Surveys (KNHANES IV) 2009. *J Clin Endocrinol Metab*. 2011;96: 3250-6. doi: 10.1210/jc.2011-1602.
6. Rantanen T, Guralnik JM, Foley D, Masaki K, Leveille S, Curb JD, White L. Midlife hand grip strength as a predictor of old age disability. *JAMA*. 1999;281:558-60. doi: 10.1001/jama.281.6.558.
7. Alkhatatbeh MJ, Abdul-Razzak KK, Khasawneh LQ, Saadeh NA. High prevalence of vitamin D deficiency and correlation of serum vitamin D with cardiovascular risk in patients with metabolic syndrome. *Metab Syndr Relat Disord*. 2017;15:213-9. doi: 10.1089/met.2017.0003.
8. Hansdottir S, Monick MM, Hinde SL, Lovan N, Look DC, Hunninghake GW. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. *J Immunol*. 2008;181:7090-9. doi: 10.4049/jimmunol.181.10.7090.
9. Canning MO, Grotenhuis K, de Wit H, Ruwhof C, Drexhage HA. 1-alpha,25-Dihydroxyvitamin D<sub>3</sub> (1,25(OH)<sub>2</sub>D<sub>3</sub>) hampers the maturation of fully active immature dendritic cells from monocytes. *Eur J Endocrinol*. 2001;145:351-7. doi: 10.1530/eje.0.1450351.
10. Tsuprykov O, Chen X, Hocher CF, Skoblo R, Lianghong Y, Hocher B. Why should we measure free 25(OH) vitamin D? *J Steroid Biochem Mol Biol*. 2018;180:87-104. doi: 10.1016/j.jsbmb.2017.11.014.
11. Bae EJ, Kim YH. Factors affecting sarcopenia in Korean adults by age groups. *Osong Public Health Res Perspect*. 2017;8:169-78. doi: 10.24171/j.phrp.2017.8.3.03.
12. Kara M, Ekiz T, Kara O, Tiftik T, Malas FU, Ozbudak Demir S, Ozgirgin N. Does vitamin D affect muscle strength and architecture? An isokinetic and ultrasonographic study. *Asia Pac J Clin Nutr*. 2017;26:85-8. doi: 10.6133/apjcn.102015.12.
13. Snijder MB, van Schoor NM, Pluijm SM, van Dam RM, Visser M, Lips P. Vitamin D status in relation to one-year risk of recurrent falling in older men and women. *J Clin Endocrinol Metab*. 2006;91:2980-5. doi: 10.1210/jc.2006-0510.
14. Kuwabara A, Tsugawa N, Kondo H, Ao M, Fujiwara H, Hosokawa N, Matsumoto S, Tanaka K, Nakano T. Associations between serum 25-hydroxyvitamin D 3 level and skeletal muscle mass and lower limb muscle strength in Japanese middle-aged subjects. *Osteoporosis & Sarcopenia*. 2017;3:53-8. doi: 10.1016/j.afos.2017.02.002.
15. Annweiler C, Schott AM, Berrut G, Fantino B, Beauchet O. Vitamin D-related changes in physical performance: a systematic review. *J Nutr Health Aging*. 2009;13:893-8. doi: 10.1007/s12603-009-0248-x.
16. Yoshimura Y, Wakabayashi H, Yamada M, Kim H, Harada A, Arai H. Interventions for treating sarcopenia: a systematic review and meta-analysis of randomized controlled studies. *J Am Med Dir Assoc*. 2017;18:553.e1-553.e16. doi: 10.1016/j.jamda.2017.03.019.
17. Beaudart C, Buckinx F, Rabenda V, Gillain S, Cavalier E, Slomian J, Petermans J, Reginster JY, Bruyere O. The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: a systematic review and meta-analysis of randomized controlled trials. *J Clin Endocrinol Metab*. 2014; 99:4336-45. doi: 10.1210/jc.2014-1742.
18. Hwang YC, Cho IJ, Jeong IK, Ahn KJ, Chung HY. Differential association between sarcopenia and metabolic phenotype in Korean young and older adults with and without obesity. *Obesity (Silver Spring)*. 2017;25:244-51. doi: 10.1002/oby.21694.
19. Verlaan S, Aspray TJ, Bauer JM, Cederholm T, Hemsworth J, Hill TR et al. Nutritional status, body composition, and quality of life in community-dwelling sarcopenic and non-sarcopenic older adults: a case-control study. *Clin Nutr*. 2017;36:267-74. doi: 10.1016/j.clnu.2015.11.013.
20. de Souza Genaro P, de Medeiros Pinheiro M, Szejnfeld VL, Martini LA. Secondary hyperparathyroidism and its relationship with sarcopenia in elderly women. *Arch Gerontol Geriatr*. 2015;60:349-53. doi: 10.1016/j.archger.2015.01.005.
21. Kim TN, Park MS, Lim KI, Choi HY, Yang SJ, Yoo HJ et al. Relationships between sarcopenic obesity and insulin resistance, inflammation, and vitamin D status: the Korean Sarcopenic Obesity Study. *Clin Endocrinol (Oxf)*. 2013;78: 525-32. doi: 10.1111/j.1365-2265.2012.04433.x.
22. Moher D, Liberati A, Tetzlaff J, Altman DG. Reprint--preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Revista Española De Nutrición Humana Y Dietética*. 2009;89:873-80. doi: 10.1093/ptj/89.9.873.

23. Duboeuf F, Braillon P, Chapuy MC, Haond P, Hardouin C, Meary MF, Delmas PD, Meunier PJ. Bone mineral density of the hip measured with dual-energy X-ray absorptiometry in normal elderly women and in patients with hip fracture. *Osteoporos Int.* 1991;1:242-9. doi: 10.1007/BF03187468.
24. Kyle UG, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Gomez JM et al. Bioelectrical impedance analysis--part I: review of principles and methods. *Clin Nutr.* 2004;23:1226-43. doi: 10.1016/j.clnu.2004.06.004.
25. Herzog R, Alvarez-Pasquin MJ, Diaz C, Del Barrio JL, Estrada JM, Gil A. Are healthcare workers' intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review. *BMC Public Health.* 2013;13:154. doi: 10.1186/1471-2458-13-154.
26. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ.* 2003;327:557-60. doi: 10.1136/bmj.327.7414.557.
27. Semba RD, Houston DK, Bandinelli S, Sun K, Cherubini A, Cappola AR, Guralnik JM, Ferrucci L. Relationship of 25-hydroxyvitamin D with all-cause and cardiovascular disease mortality in older community-dwelling adults. *Eur J Clin Nutr.* 2010;64:203-9. doi: 10.1038/ejcn.2009.140.
28. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. *Stat Med.* 2006;25:3443-57. doi: 10.1002/sim.2380.
29. Park S, Ham JO, Lee BK. A positive association between stroke risk and sarcopenia in men aged  $\geq 50$  years, but not women: results from the Korean National Health and Nutrition Examination Survey 2008-2010. *J Nutr Health Aging.* 2014;18:806-12. doi: 10.1007/s12603-014-0553-x.
30. Huo YR, Suriyaarachchi P, Gomez F, Curcio CL, Boersma D, Gunawardene P, Demontiero O, Duque G. Phenotype of sarcopenic obesity in older individuals with a history of falling. *Arch Gerontol Geriatr.* 2016;65:255-9. doi: 10.1016/j.archger.2016.04.003.
31. Oh C, Jeon BH, Reid Storm SN, Jho S, No JK. The most effective factors to offset sarcopenia and obesity in the older Korean: Physical activity, vitamin D, and protein intake. *Nutrition.* 2017;33:169-73. doi: 10.1016/j.nut.2016.06.004.
32. Kim SH, Kwon HS, Hwang HJ. White blood cell counts, insulin resistance, vitamin D levels and sarcopenia in Korean elderly men. *Scand J Clin Lab Invest.* 2017;77:228-33. doi: 10.1080/00365513.2017.1293286.
33. Ter Borg S, de Groot LC, Mijnders DM, de Vries JH, Verlaan S, Meijboom S, Luiking YC, Schols JM. Differences in nutrient intake and biochemical nutrient status between sarcopenic and nonsarcopenic older adults--results from the Maastricht Sarcopenia Study. *J Am Med Dir Assoc.* 2016;17:393-401. doi: 10.1016/j.jamda.2015.12.015.
34. Chung JY, Kang HT, Lee DC, Lee HR, Lee YJ. Body composition and its association with cardiometabolic risk factors in the elderly: a focus on sarcopenic obesity. *Arch Gerontol Geriatr.* 2013;56:270-8. doi: 10.1016/j.archger.2012.09.007.
35. Hong HC, Hwang SY, Choi HY, Yoo HJ, Seo JA, Kim SG et al. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. *Hepatology.* 2014;59:1772-8. doi: 10.1002/hep.26716.
36. Hollis BW. Comparison of commercially available (125)I-based RIA methods for the determination of circulating 25-hydroxyvitamin D. *Clin Chem.* 2000;46:1657-61.
37. Tak YJ, Lee JG, Kim YJ, Park NC, Kim SS, Lee S et al. Serum 25-hydroxyvitamin D levels and testosterone deficiency in middle-aged Korean men: a cross-sectional study. *Asian J Androl.* 2015;17:324-8. doi: 10.4103/1008-682X.142137.
38. Baecher S, Leinenbach A, Wright JA, Pongratz S, Kobold U, Thiele R. Simultaneous quantification of four vitamin D metabolites in human serum using high performance liquid chromatography tandem mass spectrometry for vitamin D profiling. *Clin Biochem.* 2012;45:1491-6. doi: 10.1016/j.clinbiochem.2012.06.030.
39. Heymsfield SB, Smith R, Aulet M, Bensen B, Lichtman S, Wang J, Pierson RN, Jr. Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry. *Am J Clin Nutr.* 1990;52:214-8. doi: 10.1093/ajcn/52.2.214.
40. Kyle UG, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Manuel Gomez J et al. Bioelectrical impedance analysis--part II: utilization in clinical practice. *Clin Nutr.* 2004;23:1430-53. doi: 10.1016/j.clnu.2004.09.012.
41. Zambrano MB, Felix TM, de Mello ED. Difference between methods for estimation of basal metabolic rate and body composition in pediatric patients with osteogenesis imperfecta. *Ann Nutr Metab.* 2018;72:21-9. doi: 10.1159/000481918.
42. Goodpaster BH, Park SW, Harris TB, Kritchevsky SB, Nevitt M, Schwartz AV et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. *J Gerontol A Biol Sci Med Sci.* 2006;61:1059-64. doi: 10.1093/gerona/61.10.1059.
43. Ceglia L. Vitamin D and skeletal muscle tissue and function. *Mol Aspects Med.* 2008;29:407-14. doi: 10.1016/j.mam.2008.07.002.
44. Koundourakis NE, Avgoustinaki PD, Malliaraki N, Margioris AN. Muscular effects of vitamin D in young athletes and non-athletes and in the elderly. *Hormones (Athens).* 2016;15:471-88. doi: 10.14310/horm.2002.1705.
45. Meng L, Man Q, Yuan L, Shen L, Li W, Guo G et al. Serum 25-hydroxyvitamin D and elderly skeletal muscle mass and function in urban north China. *Asia Pac J Clin Nutr.* 2017;26:849-55. doi: 10.6133/apjcn.072016.13.
46. Bai HJ, Sun JQ, Chen M, Xu DF, Xie H, Yu ZW et al. Age-related decline in skeletal muscle mass and function among elderly men and women in Shanghai, China: a cross sectional study. *Asia Pac J Clin Nutr.* 2016;25:326-32. doi: 10.6133/apjcn.2016.25.2.14.
47. Daly RM. Independent and combined effects of exercise and vitamin D on muscle morphology, function and falls in the elderly. *Nutrients.* 2010;2:1005-17. doi: 10.3390/nu2091005.
48. Camperi A, Pin F, Costamagna D, Penna F, Menduina ML, Aversa Z et al. Vitamin D and VDR in cancer cachexia and muscle regeneration. *Oncotarget.* 2017;8:21778-93. doi: 10.18632/oncotarget.15583.
49. Ceglia L, Niramitmahapanya S, da Silva Morais M, Rivas DA, Harris SS, Bischoff-Ferrari H, Fielding RA, Dawson-Hughes B. A randomized study on the effect of vitamin D(3) supplementation on skeletal muscle morphology and vitamin D receptor concentration in older women. *J Clin Endocrinol Metab.* 2013;98:E1927-35. doi: 10.1210/jc.2013-2820.
50. Lips P. Vitamin D deficiency and osteoporosis: the role of vitamin D deficiency and treatment with vitamin D and analogues in the prevention of osteoporosis-related fractures. *Eur J Clin Invest.* 1996;26:436-42. doi: 10.1046/j.1365-2362.1996.176290.x.



51. McKenna MJ. Differences in vitamin D status between countries in young adults and the elderly. *Am J Med.* 1992; 93:69-77. doi: 10.1016/0002-9343(92)90682-2.
52. Looker AC, Dawson-Hughes B, Calvo MS, Gunter EW, Sahyoun NR. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. *Bone.* 2002;30:771-7. doi: 10.1016/S8756-3282(02)00692-0.
53. Costa EM, Blau HM, Feldman D. 1,25-dihydroxyvitamin D3 receptors and hormonal responses in cloned human skeletal muscle cells. *Endocrinology.* 1986;119:2214-20. doi: 10.1210/endo-119-5-2214.
54. Boland R. Role of vitamin D in skeletal muscle function. *Endocr Rev.* 1986;7:434-48. doi: 10.1210/edrv-7-4-434.
55. Sorensen OH, Lund B, Saltin B, Lund B, Andersen RB, Hjorth L, Melsen F, Mosekilde L. Myopathy in bone loss of ageing: improvement by treatment with 1 alpha-hydroxycholecalciferol and calcium. *Clin Sci (Lond).* 1979; 56:157-61. doi: 10.1042/cs0560157.
56. Girgis CM, Mokbel N, Cha KM, Houweling PJ, Abboud M, Fraser DR, Mason RS, Clifton-Bligh RJ, Gunton JE. The vitamin D receptor (VDR) is expressed in skeletal muscle of male mice and modulates 25-hydroxyvitamin D (25OHD) uptake in myofibers. *Endocrinology.* 2014;155:3227-37. doi: 10.1210/en.2014-1016.
57. Schoene D, Kiesswetter E, Sieber CC, Freiburger E. Musculoskeletal factors, sarcopenia and falls in old age. *Z Gerontol Geriatr.* 2017. doi: 10.1007/s00391-017-1283-6.
58. Evans WJ. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. *Am J Clin Nutr.* 2010;91:1123s-7s. doi: 10.3945/ajcn.2010.28608A.
59. Joh HK, Lim CS, Cho B. Lifestyle and dietary factors associated with serum 25-hydroxyvitamin D levels in Korean young adults. *J Korean Med Sci.* 2015;30:1110-20. doi: 10.3346/jkms.2015.30.8.1110.
60. Bano G, Trevisan C, Carraro S, Solmi M, Luchini C, Stubbs B, Manzato E, Sergi G, Veronese N. Inflammation and sarcopenia: A systematic review and meta-analysis. *Maturitas.* 2017;96:10-5. doi: 10.1016/j.maturitas.2016.11.006.
61. Yoo JI, Ha YC, Choi H, Kim KH, Lee YK, Koo KH, Park KS. Malnutrition and chronic inflammation as risk factors for sarcopenia in elderly patients with hip fracture. *Asia Pac J Clin Nutr.* 2018;27:527-32. doi: 10.6133/apjcn.082017.02.
62. Zanetti M, Harris SS, Dawson-Hughes B. Ability of vitamin D to reduce inflammation in adults without acute illness. *Nutr Rev.* 2014;72:95-8. doi: 10.1111/nure.12095.


**Supplement table 1.** Quality assessment by using the Newcastle-Ottawa Scale for the included studies.

Author(Year)	Selection				Comparability	Outcome		Total points
	Representative of patients with sarcopenia	Sample size	Non-respondents	Ascertainment of exposure		Assessment of outcome	Statistical test	
Verlaan et al <sup>23</sup> (2017)	+			++	+	+	+	6
Oh et al <sup>35</sup> (2017)	+	+	+	+		++	+	7
Kim et al <sup>36</sup> (2017)	+		+	+	+	++	+	7
Hwang et al <sup>22</sup> (2017)	+	+	+	+		++	+	7
Ter et al <sup>37</sup> (2016)			+	++	+	++	+	7
Huo et al <sup>34</sup> (2016)		+	+	++	+	++	+	8
De et al <sup>24</sup> (2015)				+	+	++	+	5
Hong et al <sup>39</sup> (2014)	+	+		+		++	+	6
Park et al <sup>33</sup> (2014)	+	+	+	+	+	+	+	7
Kim et al <sup>25</sup> (2013)	+			+	+	++	+	6
Chung et al <sup>38</sup> (2013)	+	+	+	+	+	+	+	7
Kim et al <sup>5</sup> (2011)	+	+	+	+	+	++	+	8


**Pubmed**

((((((((((((avitaminosis) OR Ergocalciferol) OR "vitamin D deficiency") OR "hypovitaminosis D") OR calcitriol) OR cholecalciferol) OR "25-Hydroxyvitamin D 2") OR "25-Hydroxyvitamin D") OR ("Vitamin D"[Mesh] OR "Ergocalciferols"[Mesh]))) AND sarcopene\*


**Supplement figure 1.** Search strategy for “vitamin D” and “sarcopenia”.




**Supplement figure 2.** Subgroup analysis of the methods used to detect serum 25(OH)D concentrations. RIA: radioimmunoassay kit; CIA: chemiluminescence micro-particulate immunoassay; 95% CI: 95% confidence interval.




**Supplement figure 3.** Sub-analysis of the methods used to measure skeletal muscle mass. DEXA: dualenergy x-ray absorptiometry; BIA: bioelectric impedance analysis.



**Supplement figure 4.** Sub-analysis whether studies excluded obese individuals.



Supplement figure 5. Sub-analysis of the assessment criteria of sarcopenia.



Supplement figure 6. One-study-removed sensitivity analysis.